Read by QxMD icon Read

Anthracycline in breast cancer

Libo Yang, Feng Ye, Longlong Bao, Xiaoyan Zhou, Zhe Wang, Peizhen Hu, Nengtai Ouyang, Xiaojuan Li, Yi Shi, Gang Chen, Peiyi Xia, Meiying Chui, Wencai Li, Ying Jia, Liu Yueping, Junjun Liu, Junyi Ye, Zhe Zhang, Hong Bu
The correlation of genetic alterations with responding to neoadjuvant chemotherapy (NAC) is not fully revealed. In this study, we enrolled 247 breast cancers receiving anthracycline-taxane-based NAC treatment. Next generation sequencing (NGS) panel containing 36 hot spot breast cancer related genes was used in this study. Two different extent of pathologic complete response (pCR) standards, which were ypT0/isypN0 and ypT0/is, were used as indicators for NAC treatment. TP53 mutation (n = 149, 60.3%), PIK3CA mutation (n = 109, 44...
February 18, 2019: Cancer Science
Milita Zaheed, Nicholas Wilcken, Melina L Willson, Dianne L O'Connell, Annabel Goodwin
BACKGROUND: Anthracyclines and taxanes are chemotherapeutic agents widely used in a sequential regimen in the adjuvant and neoadjuvant treatment of early breast cancer to reduce the risk of cancer recurrence. Standard practice is to administer anthracycline-based chemotherapy followed by a taxane. Anthracyclines tend to be administered first as they were established before taxanes for treatment of early breast cancer. OBJECTIVES: To assess whether the sequence in which anthracyclines and taxanes are administered affects outcomes for people with early breast cancer receiving adjuvant or neoadjuvant therapy...
February 18, 2019: Cochrane Database of Systematic Reviews
Oscar Calvillo-Argüelles, Husam Abdel-Qadir, Maria Michalowska, Filio Billia, Sivisan Suntheralingam, Eitan Amir, Paaladinesh Thavendiranathan
BACKGROUND: Statins can reduce the risk of anthracycline-induced cardiotoxicity. Whether such cardioprotective effects can be seen in trastuzumab-treated patients has not been explored. METHODS: Consecutive women with HER2+ breast cancer who received trastuzumab with or without anthracyclines were identified retrospectively. Patients receiving statins before and during cancer treatment were matched with 2 patients of the same age (± 2 years) and anthracycline exposure status but without statin treatment...
February 2019: Canadian Journal of Cardiology
Allison Padegimas, Suparna Clasen, Bonnie Ky
Breast cancer is the most common malignancy affecting females, with over 260,000 new cases annually and over 3.1 million survivors in the United States alone. Exposure to potentially cardiotoxic therapies, including anthracyclines, trastuzumab, and radiation therapy, coupled with host factors, place patients at increased risk for the development of cardiovascular disease (CVD) compared to non-cancer controls. Overall survival outcomes are significantly worse in patients who develop CVD, and in certain breast cancer populations, cardiovascular death exceeds the risk of cancer death in the long-term...
January 29, 2019: Trends in Cardiovascular Medicine
(no author information available yet)
BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. METHODS: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy...
February 7, 2019: Lancet
Luis Manso, Fernando Moreno Antón, Yann Izarzugaza Perón, Juan I Delgado Mingorance, Pablo Borrega García, María J Echarri González, Noelia Martínez-Jañez, Ana López-González, Clara Olier Garate, Anabel Ballesteros García, Ignacio Chacón López-Muñíz, Eva Ciruelos Gil, Jose Angel García-Sáenz, Luis Paz-Ares
Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients. Few safety data have been published in third line. We aimed to report the specific safety profile on third line beyond taxanes and anthracyclines in advanced breast cancer (ABC). A multicenter phase II, prospective study was conducted in anthracyclines and taxanes pre-treated HER2-negative ABC, programmed to receive eribulin as third-line chemotherapy. Adverse events (AEs) were assessed and classified according to CTCAE. In addition, efficacy, in terms of overall survival (OS) and progression-free survival (PFS), and the dynamics of circulating tumor cells (CTCs) during treatment were assessed...
February 8, 2019: Breast Journal
Kristina Iribarren, Aitziber Buque, Laura Mondragon, Wei Xie, Sarah Lévesque, Jonathan Pol, Laurence Zitvogel, Oliver Kepp, Guido Kroemer
The treatment of breast cancer largely depends on the utilization of immunogenic chemotherapeutics, which, as a common leitmotif, stimulate the exposure of calreticulin (CALR) on the surface of cancer cells, thereby facilitating their recognition by dendritic cells for the uptake of tumor-associated antigens and subsequent antigen cross-presentation to cytotoxic T cells. Breast cancer cells also express the calreticulin antagonist CD47, which inhibits tumor cell phagocytosis and consequently subverts anticancer immune responses...
2019: Oncoimmunology
Jahae Kim, Sang-Geon Cho, Sae-Ryung Kang, Su Woong Yoo, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Ho-Chun Song
BACKGROUND: The aim of this study was to investigate changes in myocardial uptake evaluated by oncologic 18 F-fluorodeoxyglucose (FDG) PET/CT scans and to determine the relationship between myocardial FDG uptake and cancer therapy-induced cardiotoxicity in breast cancer patients who underwent anthracycline or trastuzumab. METHODS: We reviewed 121 consecutive patients who underwent oncologic FDG PET/CT and echocardiography at baseline and post-therapy with anthracyclines or trastuzumab for breast cancer...
February 4, 2019: Journal of Nuclear Cardiology: Official Publication of the American Society of Nuclear Cardiology
Husam Abdel-Qadir, Paaladinesh Thavendiranathan, Peter C Austin, Douglas S Lee, Eitan Amir, Jack V Tu, Kinwah Fung, Geoffrey M Anderson
Background: Data are limited regarding the risk of heart failure (HF) requiring hospital-based care after early stage breast cancer (EBC) and its relationship to other types of cardiovascular disease (CVD). Methods: We conducted a population-based, retrospective cohort study of EBC patients (diagnosed April 1, 2005-March 31, 2015) matched 1:3 on birth-year to cancer-free control subjects. We identified hospitalizations and emergency department visits for CVD through March 31, 2017...
January 31, 2019: Journal of the National Cancer Institute
Quanfu Li, Yungaowa Wu, Wenjuan Wang, Shuqin Deng, Caihong Jiang, Feng Chen, Jun Zhao, Hui Li, Xiaojun Bai, Jixiang Hou, Lenggaowa Da, Lanzhen Zhao, Jiali Gao, Gaowa Jin
OBJECTIVE: To assess the safety and efficacy of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline chemotherapy-induced nausea and vomiting. METHODS: One hundred patients with breast cancer from department of Medical Oncology of Ordos Central Hospital from June 2015 to February 2018 were selected and randomize subdivided into 2 groups. All cases received anthracycline (30 mg/m2 /d for pirarubicin or 45 mg/m2 /d for epirubicin) and cyclophosphamide adjuvant chemotherapy, along with either the standard therapy (dexamethasone and tropisetron) or the combined aprepitant therapy (aprepitant plus dexamethasone and tropisetron)...
January 23, 2019: Current Problems in Cancer
Kan Yonemori, Akihiko Shimomura, Hiroyuki Yasojima, Norikazu Masuda, Kenjiro Aogi, Masato Takahashi, Yoichi Naito, Satoru Shimizu, Rikiya Nakamura, Jun Hashimoto, Harukaze Yamamoto, Akihiro Hirakawa, Hirofumi Michimae, Akinobu Hamada, Teruhiko Yoshida, Tamie Sukigara, Kenji Tamura, Yasuhiro Fujiwara
BACKGROUND: We conducted a multicenter phase I/II trial of olaparib plus eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer (TNBC) to determine the recommended phase II dose (RP2D) (phase I) and to examine the efficacy and safety (phase II) (UMIN00009498) of the combined therapy. PATIENTS AND METHODS: In phase I, olaparib tablet was orally administered twice daily from level 1:25 mg BID to level 7:300 mg BID, with 1.4 mg/m2 of eribulin on days 1 and 8...
January 28, 2019: European Journal of Cancer
Chih-Hsin Lee, Jun-Fu Zhang, Kevin Sheng-Po Yuan, Alexander T H Wu, Szu-Yuan Wu
PURPOSE: The risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy (CT) and radiotherapy (RT) is yet to be investigated in a large-scale randomized controlled trial with an adequate sample size of young and old women with breast cancer. PATIENTS AND METHODS: To compare the occurrence of major heart events (heart failure and coronary artery disease) in patients with breast cancer, 3489 women who underwent surgical resection of the breast tumor were retrospectively selected from the Taiwan National Health Insurance Research Database...
January 28, 2019: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Nan Soon Wong
Primary systemic therapy (PST) is a widely adopted strategy for increasing operability and breast conservation rates. Although first generation PST trials failed to demonstrate improvements in disease free and overall survival compared to adjuvant systemic therapy (AST), they did demonstrate a strong association between attainment of pathologic complete response (pCR) and improved survival outcomes, leading to the widespread adoption of pCR as the primary endpoint in subsequent PST trials. First generation trials also showed that preoperative PST can improve breast conservation rates and downstage the axilla...
December 2018: Gland Surgery
Lucia D'Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I Wolter, Roger R Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic, Ulf Grawunder, Sai Reddy, Alfred Zippelius
Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a novel HER2-targeting ADC bearing a potent anthracycline derivate as payload (T-PNU) in a human HER2-expressing syngeneic breast cancer model resistant to trastuzumab and ado-trastuzumab emtansine. Mechanistically, the anthracycline component of the novel ADC induced immunogenic cell death leading to exposure and secretion of danger-associated molecular signals...
January 21, 2019: Journal for Immunotherapy of Cancer
Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria, Robert Gray, Elisabetta Munzone, Jerome Lemonnier, Christos Sotiriou, Martine J Piccart, Pirkko-Liisa Kellokumpu-Lehtinen, Andrea Vingiani, Kathryn Gray, Fabrice Andre, Carsten Denkert, Roberto Salgado, Stefan Michiels
PURPOSE: The aim of the current study was to conduct a pooled analysis of studies that have investigated the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage triple negative breast cancer (TNBC). METHODS: Participating studies had evaluated the percentage infiltration of stromally located TILs (sTILs) that were quantified in the same manner in patient diagnostic samples of early-stage TNBC treated with anthracycline-based chemotherapy with or without taxanes...
January 16, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Alina Bisoc, Daniel Ciurescu, Mariana Rădoi, Monica M Tântu, Liliana Rogozea, Alexander J Sweidan, Daniela A Bota
BACKGROUND: Anthracyclines remain the cornerstone of the treatment in many cancers including lymphomas, leukemia and sarcomas, and breast cancer. The cardiomyopathy that develops from anthracyclines can lead to heart failure and decreased survival. Multiple mechanisms are involved in the pathophysiology of anthracycline-induced heart failure. STUDY QUESTION: We hypothesize that anthracycline-induced cardiac (AIC) pathology can be monitored using a panel of blood biomarkers including high-sensitive cardiac troponin T (hs-cTnT) for myocyte necrosis and N-terminal prohormone brain natriuretic peptide (NT-proBNP) for parietal stress...
January 3, 2019: American Journal of Therapeutics
Amy A Kirkham, D Ian Paterson, Carla M Prado, John R Mackey, Kerry S Courneya, Edith Pituskin, Richard B Thompson
Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly.
January 15, 2019: BMC Cancer
Silvia Antolín, Benigno Acea, Luis Albaina, Ángel Concha, Paz Santiago, Tomás García-Caballero, Joaquín J Mosquera, José Ramón Varela, Rafaela Soler, Lourdes Calvo
Objective: The aim of this study was to evaluate the efficacy, cardiotoxicity profile and long-term benefits of neoadjuvant therapy in human epidermal growth factor receptor 2-positive operable breast cancer patients. Patients and methods: A total of 142 patients diagnosed from 2005 to 2016 were included in the study. The treatment consisted of a sequential regimen of taxanes and anthracyclines plus trastuzumab. The clinical and pathological responses were evaluated and correlated with clinical and biological factors...
2019: Breast Cancer: Targets and Therapy
Yang Anqi, Zhang Yu, Xu Mingjun, Kong Xiaoli, Li Mengmeng, Liu Fangfang, Zhang Mei
BACKGROUND: Anthracycline-related cardiotoxicity has a poor prognosis; therefore, early detection of any change in LV function is critical. OBJECTIVE: The aim of this study was to evaluate the two-dimensional speckle tracking technique for the early detection of cardiac toxicity after low-dose anthracycline chemotherapy in the Chinese population. METHODS: Forty breast cancer patients were treated by chemotherapy using anthracycline for 4-6 cycles...
January 12, 2019: Echocardiography
Rhys I Beaudry, Erin J Howden, Steve Foulkes, Ashley Bigaran, Piet Claus, Mark J Haykowsky, Andre La Gerche
Women with early-stage breast cancer have reduced peak exercise oxygen uptake (peak VO2 ). The purpose of this study was to evaluate peak VO2 and right (RV) and left (LV) ventricular function prior to adjuvant chemotherapy. Twenty-nine early-stage breast cancer patients (mean age: 48 years) and 10 age-matched healthy women were studied. Participants performed an upright cycle exercise test with expired gas analysis to measure peak VO2 . RV and LV volumes and function were measured at rest, submaximal and peak supine cycle exercise using cardiac magnetic resonance imaging...
January 2019: Physiological Reports
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"